Childhood/adulthood adiposity · women with gestational diabetes mellitus
1 finding from 1 review
Childhood/adulthood diabetes · women with gestational diabetes mellitus
1 finding from 1 review
Neurosensory disability · women with gestational diabetes mellitus
1 finding from 1 review
Hypertensive disorders of pregnancy · women with gestational diabetes mellitus
1 finding from 1 review
Caesarean section · women with gestational diabetes mellitus
1 finding from 1 review
Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea ( compared with placebo (low certainty).
1 finding from 1 review
Participant preference · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher participant preference ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher withdrawal any reason ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal due to lack of efficacy ( compared with other anti‐emetic agent (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher withdrawal due to adverse event ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher absence of vomiting ( compared with placebo (low certainty).
1 finding from 1 review
Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids probably leads to higher absence of nausea and vomiting ( compared with placebo (moderate certainty).
1 finding from 1 review
Participant preference · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher participant preference ( compared with placebo (low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal any reason ( compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal due to adverse event ( compared with placebo (very low certainty).
1 finding from 1 review
Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of vomiting ( compared with other anti‐emetic agent (moderate certainty).
1 finding from 1 review
Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Irinotecan‐based regimens showed no clear difference in overall survival compared with irinotecan (low certainty).
1 finding from 1 review
Tumour response · people with metastatic CRC
Irinotecan‐based regimens leads to higher overall tumour response compared with irinotecan (high certainty).
1 finding from 1 review